← Search & browse all drugs

medroxyprogesterone

G03DA02

Forms & Strengths

Oral tablets: 2.5 mg, 5 mg, 10 mg
Injectable suspension (Depo-Provera): 150 mg/mL
Subcutaneous injectable suspension (Depo-SubQ Provera 104): 104 mg/0.65 mL

Adult Dosing

Secondary amenorrhea: 5 to 10 mg orally daily for 5 to 10 days
Abnormal uterine bleeding: 5 to 10 mg orally daily for 5 to 10 days starting on day 16 or 21 of cycle
Contraception: 150 mg deep IM every 3 months or 104 mg subcutaneous every 3 months
Endometrial or renal carcinoma: 400 to 1000 mg IM weekly initially

Pediatric Dosing

Contraception (adolescents): 150 mg deep IM every 3 months or 104 mg subcutaneous every 3 months
Endometriosis/precocious puberty: Safety and efficacy not established for routine pediatric use outside specialized endocrine indications

Indications

Contraception
Secondary amenorrhea
Abnormal uterine bleeding due to hormonal imbalance
Endometrial or renal carcinoma (palliation)
Endometriosis-associated pain (SubQ formulation)

Mechanism of Action

Synthetic progestin that inhibits pituitary gonadotropin secretion (FSH and LH)
Prevents follicular maturation and ovulation
Thins the endometrium and thickens cervical mucus to inhibit sperm penetration

Contraindications

Known or suspected pregnancy
Active thrombophlebitis or thromboembolic disorders
Liver dysfunction or disease
Known or suspected malignant neoplasm of the breast
Undiagnosed abnormal vaginal bleeding
Hypersensitivity to medroxyprogesterone

Adverse Reactions

Menstrual irregularities (amenorrhea, heavy bleeding, spotting)
Weight gain
Headache
Dizziness
Decreased bone mineral density
Depression
Injection site reactions

Drug Interactions

CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort) may decrease serum concentrations and contraceptive efficacy
Aminoglutethimide may significantly reduce medroxyprogesterone plasma levels
May alter glucose tolerance and efficacy of antidiabetic agents

Curated Content: Needs Vetting Before Put to Clinical Use